3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Warts
2
Virus Diseases
1
Skin Diseases, Viral
1
Skin Diseases, Infectious
1
Skin Diseases
1
Sexually Transmitted Diseases, Viral
1
Sexually Transmitted Diseases
1
Papillomavirus Infections
1
Condylomata Acuminata
1
Interventions
binimetinib
2
Watchful Waiting
2
Aminolevulinic Acid
2
palbociclib
1
ipatasertib
1
exemestane
1
encorafenib
1
baricitinib
1
atezolizumab
1
Vemurafenib
1
VP-102
1
Trabectedin
1
Paclitaxel
1
Injections, Intradermal
1
Gonadotropin-Releasing Hormone
1
Everolimus
1
Dacarbazine
1
Cantharidin
1
BF-200 ALA
1
Anastrozole
1
AZD9833
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Skin Diseases
×
VP-102
×
Clear all
NCT03981822
2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
105 enrolled
24 charts